Gyre Therapeutics, Inc. Common Stock (GYRE) Stock Price

GYREStock

$6.68−21.27%52W

Market Cap$708.31M

P/E146.60x

PEG Ratio—

Div yield—

Beta2.37

GYRE Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-32.81%

Price vs S&P 500 (4W)4.46%

VGM Score40.20

P/E Ratio (Annual)146.60x

P/CF (Annual)729.64x

Book Value / Share (Quarterly)$1.11

P/TBV (Annual)6.42x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)428.46%

Cash Flow / Share (Quarterly)$0.03

Price vs S&P 500 (YTD)-20.74%

Gross Margin (TTM)95.09%

Net Profit Margin (TTM)-5.44%

EPS (TTM)$-0.08

10-Day Avg Trading Volume0.06M

EPS Excl Extra (TTM)$-0.08

Revenue Growth (5Y)40.96%

EPS (Annual)$0.05

ROI (Annual)4.74%

Gross Margin (Annual)95.35%

Net Profit Margin (5Y Avg)-461.44%

Cash / Share (Quarterly)$0.55

P/E Basic Excl Extra (TTM)116.93x

Revenue Growth QoQ (YoY)2.09%

P/E Normalized (Annual)146.60x

ROA (Last FY)3.03%

Revenue Growth TTM (YoY)16.30%

EBITD / Share (TTM)$0.03

ROE (5Y Avg)-90.40%

Operating Margin (TTM)-0.12%

Cash Flow / Share (Annual)$-0.01

P/B Ratio7.27x

P/B Ratio (Quarterly)6.28x

Net Income / Employee (Annual)$8,100

EV / Revenue (TTM)5.98x

Net Interest Coverage (TTM)-14.38x

ROA (TTM)-3.98%

EPS Growth QoQ (YoY)215.45%

EV / EBITDA (TTM)282.37x

EPS Incl Extra (Annual)$0.05

Current Ratio (Annual)5.60x

Quick Ratio (Quarterly)3.87x

3-Month Avg Trading Volume0.08M

52-Week Price Return-21.27%

P/E Incl Extra (TTM)116.93x

Revenue / Employee (TTM)$189,400

Tangible BV / Share (Quarterly)$1.06

P/S Ratio (Annual)6.32x

Asset Turnover (Annual)0.70x

52-Week High$9.42

Operating Margin (5Y Avg)-459.73%

EPS Excl Extra (Annual)$0.05

CapEx CAGR (5Y)45.00%

Tangible BV CAGR (5Y)-17.70%

26-Week Price Return-21.56%

Quick Ratio (Annual)4.97x

13-Week Price Return4.21%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)4.64x

Enterprise Value$699.44M

Revenue / Share Growth (5Y)-41.41%

Asset Turnover (TTM)0.73x

Book Value / Share Growth (5Y)-42.88%

Revenue / Employee (Annual)$188,700

Inventory Turnover (Annual)0.66x

Pretax Margin (Annual)12.38%

Cash / Share (Annual)$0.57

3-Month Return Std Dev54.31%

Gross Margin (5Y Avg)57.41%

Net Income / Employee (TTM)$-10,300

ROE (Last FY)4.74%

EPS Basic Excl Extra (Annual)$0.05

P/FCF (TTM)83.75x

Receivables Turnover (TTM)5.46x

EV / Free Cash Flow (TTM)230.53x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.08

Receivables Turnover (Annual)4.60x

ROI (TTM)-6.34%

P/S Ratio (TTM)6.30x

Pretax Margin (5Y Avg)-446.04%

Revenue / Share (Annual)$1.13

Tangible BV / Share (Annual)$1.09

Forward P/E195.13x

Price vs S&P 500 (52W)-39.58%

P/E Ratio (TTM)116.93x

EPS Growth TTM (YoY)-60.17%

Year-to-Date Return-8.78%

5-Day Price Return-7.74%

EPS Normalized (Annual)$0.05

ROA (5Y Avg)-50.79%

Net Profit Margin (Annual)4.31%

Month-to-Date Return12.00%

Cash Flow / Share (TTM)$-18.23

EBITD / Share (Annual)$0.14

Operating Margin (Annual)9.85%

LT Debt / Equity (Annual)0.00x

P/CF (TTM)170.63x

ROI (5Y Avg)-90.40%

P/E Excl Extra (TTM)116.93x

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-0.08

P/TBV (Quarterly)6.58x

P/B Ratio (Annual)6.05x

Inventory Turnover (TTM)0.60x

Pretax Margin (TTM)0.48%

Book Value / Share (Annual)$1.16

Price vs S&P 500 (13W)1.41%

Beta2.37x

P/FCF (Annual)42.58x

Revenue / Share (TTM)$1.28

ROE (TTM)-6.34%

52-Week Low$5.44

vGradeD

gGradeC

mGradeD

vgmGradeC

GYRE Earnings Surprise History

Q2 250.00est. 0.03

Q3 250.03est. -0.02

Q4 250.05est. 0.01

Q1 26-0.10est. -0.07

Q2 26-0.12est. -0.06

GYRE Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.22

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
GYREGyre Therapeutics, Inc. Common Stock	D	C	D	$6.68
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Gyre Therapeutics, Inc. Common Stock

Gyre Therapeutics is a commercial-stage biopharmaceutical company specializing in small-molecule anti-inflammatory and anti-fibrotic therapies for organ fibrosis. The company commercializes ETUARY, Avatrombopag, and Nintedanib, while advancing Hydronidone (F351) for metabolic dysfunction-associated steatohepatitis liver fibrosis and a pipeline of earlier-stage candidates in China. Primary revenue derives from ETUARY and generic pharmaceutical sales in mainland China.